	US 12,228,582 B2
	Method and apparatus for testing near infrared-photoimmunotherapy treatment
Hisataka Kobayashi, Bethesda, MD (US); and Masayuki Nishimura, Columbia, MD (US)
Assigned to SHIMADZU CORPORATION, Kyoto (JP); and The United States of America as Represented By The Secretary of the Department of Health and Human, Bethesda, MD (US)
Appl. No. 17/253,671
Filed by SHIMADZU CORPORATION, Kyoto (JP); and THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
PCT Filed Jun. 20, 2019, PCT No. PCT/US2019/038097 § 371(c)(1), (2) Date Dec. 18, 2020, PCT Pub. No. WO2019/246322, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/688,031, filed on Jun. 21, 2018.
Prior Publication US 2021/0263054 A1, Aug. 26, 2021
Int. Cl. G01N 33/94 (2006.01); A61K 41/00 (2020.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/94 (2013.01) [A61K 41/0042 (2013.01); A61K 41/0071 (2013.01); A61K 47/6849 (2017.08); A61K 47/6855 (2017.08); C07K 16/2863 (2013.01); G01N 33/6848 (2013.01)]

8 Claims

1. A method for testing efficiency and effectiveness of a near infrared photoimmunotherapy treatment, the method comprising:

injecting an antibody photosensitizer conjugate into a patient, wherein the antibody photosensitizer conjugate comprises an antibody conjugated to a C₇₄H₉₆N₁₂Na₄O₂₇S₆Si₃phthalocyanine dye;

applying radiation to the patient, thereby causing the antibody photosensitizer conjugate to release a C₁₄H₃₃NO₁₀S₃Si ligand, which is excreted in the patient's urine;

detecting the presence of the C₁₄H₃₃NO₁₀S₃Si ligand with liquid chromatography-mass spectrometry; and

measuring and quantifying an amount of the C₁₄H₃₃NO₁₀S₃Si ligand present in the patient's urine based on analytical results of the liquid chromatography-mass spectrometry to determine the efficiency and effectiveness of the near infrared photo-immunotherapy treatment,

wherein the amount of the C₁₄H₃₃NO₁₀S₃Si ligand present in the patient's urine inversely corresponds to an amount of an antibody photosensitizer conjugate remaining in the patient, and

wherein the amount of the C₁₄H₃₃NO₁₀S₃Si ligand present in the patient's urine positively corresponds with the efficiency and effectiveness of the near infrared photoimmunotherapy treatment.